Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

Cancers, Год журнала: 2024, Номер 16(17), С. 2975 - 2975

Опубликована: Авг. 27, 2024

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.

Язык: Английский

---

Tandem CAR-T cell therapy: recent advances and current challenges

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 28, 2025

CAR-T cell therapy has revolutionized cancer treatment. However, despite the achievements of this approach, there are still clinical challenges to address, such as antigen loss and design an optimal CAR structure. Multi-targeted therapies, including tandem cells, have emerged a strategy overcome some these limitations improve outcomes. Tandem cells currently being evaluated in preclinical studies for treatment hematological malignancies solid tumors, showing promising results. These CARs demonstrated efficacy, safety, relatively low relapse rate studies. Research suggests that TanCAR-T can enhance outcomes benefits therapy. identifying ideal construct, selecting appropriate targets, improving transduction efficiency remain unresolved, further research is essential address limitations. This review highlights potential treatment, summarizing with innovative emphasizing importance continued its effectiveness.

Язык: Английский

---

Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(2), С. 90 - 90

Опубликована: Янв. 31, 2025

Chimeric antigen receptor-T (CAR-T) cell therapy has demonstrated impressive efficacy in the treatment of blood cancers; however, its effectiveness against solid tumors been significantly limited. The differences arise from a range difficulties linked to tumors, including an unfriendly tumor microenvironment, variability within and barriers CAR-T infiltration longevity at location. Research shows that reasons for decreased cells treating are not well understood, highlighting ongoing need strategies address these challenges. Current frequently incorporate combinatorial therapies designed boost functionality enhance their capacity effectively target tumors. However, remain testing phase necessitate additional validation assess potential benefits. CAR-NK (natural killer), CAR-iNKT (invariant natural killer T), CAR-M (macrophage) emerging as promising Recent studies highlight construction optimization cells, emphasizing overcome unique challenges posed by such hypoxia metabolic barriers. This review focuses on CAR

Язык: Английский

---

Induced Mesenchymal Stem Cells: An Emerging Source for Regenerative Medicine Applications

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(6), С. 2053 - 2053

Опубликована: Март 18, 2025

Regenerative medicine is gaining interest in the medical field due to limitations of conventional treatments, which often fail address underlying cause disease. In recent years, stem cell-based therapies have evolved as a promising alternative approach treat those diseases that cannot be cured using medicine. Adult cells, particularly mesenchymal cells (MSCs), attracted lot attention their ability regenerate and repair human tissues organs. MSCs isolated from adult are well characterized currently most common type for use regenerative However, low number donor tissues, donor-age cell-source related heterogeneity, limited proliferative differentiation potential, early senescence vitro cultures, negatively affect MSC potential. These factors restrict research clinical applications. To overcome these problems, with superior potential required. Induced (iMSCs) obtained induced pluripotent (iPSCs). patient-specific, readily available, relatively and, therefore, can problems associated primary MSCs. this review, authors aim discuss characteristics, The main methods generate iMSCs iPSCs been discussed detail. addition, proposed criteria molecular characterization, applications disease modeling drug discovery, explored

Язык: Английский

---

Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(22), С. 11927 - 11927

Опубликована: Ноя. 6, 2024

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Due to its nonspecific symptoms and unreliable screening tools, EOC not diagnosed at an early stage in cases. Unfortunately, despite achieving initial remission after debulking surgery platinum-based chemotherapy, patients experience recurrence of disease. The limited therapy approaches have encouraged scientists search for new detection therapeutic strategies. In this review, we discuss role folate receptor alpha (FRα) development potential application as a biomarker molecular target designing treatment methods. We summarize mechanisms action various strategies based on FRα, including MABs (monoclonal antibodies), ADCs (antibody-drug conjugates), FDCs (folate-drug SMDCs (small molecule-drug vaccines, CAR-T (chimeric antigen T) cells, present significant clinical trials some FRα-based drugs. Furthermore, pros cons different FR-based therapies, highlighting mirvetuximab soravtansine (MIRV) currently promising EOC-targeting drug.

Язык: Английский

---

Bidirectional Prime Editing: Combining Precision with Versatility for Genome Editing

Cellular Reprogramming, Год журнала: 2024, Номер unknown

Опубликована: Дек. 17, 2024

Genome editing techniques have potential to revolutionize the field of life sciences. Several limitations associated with traditional gene been resolved development prime editors that precisely edit DNA without double-strand breaks (DSBs). To further improve efficiency, several modified versions (PE) system introduced. Bi-directional PE (Bi-PE), for example, uses two guide RNAs enabling broad and improved efficiency. It has alter, delete, integrate, replace larger genome sequences multiple bases at same time. This review aims discuss typical methods offer DSB-mediated repair mechanisms, followed by latest advances in technologies non-DSB-mediated repair. The specifically focuses on Bi-PE being an efficient tool human genome. In addition, discusses applications, limitations, future perspectives editing.

Язык: Английский

---

NOVEL THERAPEUTIC APPROACHES TARGETING CANCER STEM CELLS: UNVEILING NEW FRONTIERS IN BREAST CANCER TREATMENT

Pathology - Research and Practice, Год журнала: 2024, Номер 266, С. 155800 - 155800

Опубликована: Дек. 26, 2024

Язык: Английский

---